接种 gp41 预发夹融合中间态肽模拟物可产生针对 HIV-1 分离株的中和抗体。
Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates.
机构信息
Department of Peptide Chemistry, Merck Research Laboratories, Pomezia, 00040 Rome, Italy.
出版信息
Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10655-60. doi: 10.1073/pnas.1004261107. Epub 2010 May 18.
Eliciting a broadly neutralizing polyclonal antibody response against HIV-1 remains a major challenge. One approach to vaccine development is prevention of HIV-1 entry into cells by blocking the fusion of viral and cell membranes. More specifically, our goal is to elicit neutralizing antibodies that target a transient viral entry intermediate (the prehairpin intermediate) formed by the HIV-1 gp41 protein. Because this intermediate is transient, a stable mimetic is required to elicit an immune response. Previously, a series of engineered peptides was used to select a mAb (denoted D5) that binds to the surface of the gp41 prehairpin intermediate, as demonstrated by x-ray crystallographic studies. D5 inhibits the replication of HIV-1 clinical isolates, providing proof-of-principle for this vaccine approach. Here, we describe a series of peptide mimetics of the gp41 prehairpin intermediate designed to permit a systematic analysis of the immune response generated in animals. To improve the chances of detecting weak neutralizing polyclonal responses, two strategies were employed in the initial screening: use of a neutralization-hypersensitive virus and concentration of the IgG fraction from immunized animal sera. This allowed incremental improvements through iterative cycles of design, which led to vaccine candidates capable of generating a polyclonal antibody response, detectable in unfractionated sera, that neutralize tier 1 HIV-1 and simian HIV primary isolates in vitro. Our findings serve as a starting point for the design of more potent immunogens to elicit a broadly neutralizing response against the gp41 prehairpin intermediate.
激发针对 HIV-1 的广泛中和多克隆抗体反应仍然是一个主要挑战。疫苗开发的一种方法是通过阻断病毒和细胞膜的融合来阻止 HIV-1 进入细胞。更具体地说,我们的目标是引发针对 HIV-1 gp41 蛋白形成的瞬时病毒进入中间物(发夹前中间物)的中和抗体。由于这种中间物是瞬时的,因此需要稳定的模拟物来引发免疫反应。以前,使用一系列工程肽来选择与 gp41 发夹前中间物表面结合的 mAb(表示为 D5),这已通过 X 射线晶体学研究证明。D5 抑制 HIV-1 临床分离物的复制,为这种疫苗方法提供了原理证明。在这里,我们描述了一系列 gp41 发夹前中间物的肽模拟物,旨在对动物中产生的免疫反应进行系统分析。为了提高检测弱中和多克隆反应的机会,在初始筛选中采用了两种策略:使用中和敏感病毒和浓缩免疫动物血清中的 IgG 部分。这通过设计的迭代循环允许逐步改进,从而产生能够在未分级血清中检测到的多克隆抗体反应的候选疫苗,该反应可中和体外的 HIV-1 第 1 层和猿猴 HIV 原始分离物。我们的发现为设计更有效的免疫原以引发针对 gp41 发夹前中间物的广泛中和反应提供了起点。